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Mycobacterium bovis Bacillus Calmette-Gu´ erin (BCG) as a live vector of recombinant bacterial vaccine is a promising system to
be used. In this study, we evaluate the disrupted expression of heterologous HIV-1gp120 gene in BCG Pasteur host strain using
replicative vectors pMV261 and pJH222. pJH222 carries a lysine complementing gene in BCG lysine auxotrophs. The HIV-1
gp120 gene expression was regulated by BCG hsp60 promoter (in plasmid pMV261) and Mycobacteria spp. α-antigen promoter
(in plasmid pJH222). Among 14 rBCG:HIV-1gp120 (pMV261) colonies screened, 12 showed a partial deletion and two showed
a complete deletion. However, deletion was not observed in all 10 rBCG:HIV-1gp120 (pJH222) colonies screened. In this study,
we demonstrated that E. coli/Mycobacterial expression vectors bearing a weak promoter and lysine complementing gene in a
recombinant lysine auxotroph of BCG could prevent genetic rearrangements and disruption of HIV 1gp120 gene expression, a key
issue for engineering Mycobacterial based vaccine vectors.
1.Introduction
The need for a safe and eﬀective human immunodeﬁciency
virus (HIV) vaccine has never been greater. The acquired
immune deﬁciency syndrome (AIDS) epidemic update
released by UNAIDS on December 2009, documented that
the overall number of people with HIV has stabilized, albeit
at an unacceptably high level of about 33.4 million people
living with HIV and 2.7 million individuals being newly
infected with the virus in 2008. The global AIDS epidemics
killed 2 million people in 2008, and the number of children
orphaned by AIDS may reach 25 millions by 2010. About
85% of these new infections occur in developing countries
where access to antiretrovirals is still an enormous challenge
[1, 2].
T h e r ei ss t r o n ge v i d e n c et os u p p o r tar o l eo fc y t o -
toxic T lymphocytes (CTLs) in the containment of HIV
replication [3–6] and several vaccine approaches have been
pursuedtoelicitanti-HIVCTLresponses[7].Onepromising
approach is to use Mycobacterium bovis Bacillus Calmette-
Gu´ erin (BCG) as a live recombinant bacterial vaccine vector.
BCG vaccine has been used to immunize more than two
billion individuals against tuberculosis with a long record
of eﬀectiveness and safety for use in humans [8]. CTL
inductionagainstHIV-1andsimianimmunodeﬁciencyvirus
(SIV) gag or env antigens has been described following
the immunization of mice or nonhuman primates with
recombinant BCG (rBCG) expressing these antigens [8, 9].
More recently, recombinant Mycobacterium bovis Bacillus
Calmette-Gu´ erin (BCG) expressing HIVA immunogen has2 Journal of Biomedicine and Biotechnology
been generated and shown to be stable and to induce
durable and high-quality HIV-1-speciﬁc CD4+ and CD8+
T-cell responses in BALB/c mice. Furthermore, when the
recombinant BCG vaccine was used in a priming-boosting
regimen with heterologous components, the HIV-1-speciﬁc
responses provided protection against surrogate virus chal-
lenge, and the recombinant BCG vaccine alone protected
against aerosol challenge with M. tuberculosis [10].
Three issues are critical for engineering a stable and
immunogenic mycobacterial-based vaccine vector: (i) anti-
gen localization, (ii) codon optimization, and (iii) in vivo
plasmidDNAstabilityandgeneticrearrangements.Theanti-
gen secretion and fusion of foreign antigens to mycobacterial
surface lipoproteins will provide these antigens with access
to the major histocompatibility complex (MHC) class I
pathway and subsequently enhance the immunogenicity and
to prevent foreign proteins from becoming toxic to BCG
[11]. The use of mycobacterial optimal codons will enhance
the transcriptional/translational activity of the foreign gene.
The plasmid stability in vivo is essential for heterologous
gene expression [8].
Genetic rearrangements have been described occurring
in eukaryotes and prokaryotes [12]. Homologous recombi-
nation, which takes place between repeated DNA sequences,
is one of the most important mechanisms for bacterial
genome rearrangements. Any repeated DNA sequences on
a chromosome can induce homologous recombination, but
insertion sequences (IS) are among the most abundant
of these [13–15]. Mycobacteria have been reported to
contain several IS. In Mycobacterium tuberculosis,i th a sb e e n
suggested that IS6110 is an important source of genome
variation. However, the role of such IS elements has not
been thoroughly explored in heterologous gene expression in
mycobacteria [16–18].
Expression of heterologous antigen in recombinant BCG
necessarily imposes a metabolic burden. The extent of this
burden will determine the degree to which ﬁtness of the
recombinant BCG is compromised. Thus, the relative level
of ﬁtness of the recombinant and any derived mutants will
determine the rate at which the inserted element (structural
instability) or its expression (functional instability) is lost
from the bacterial population [19].
Husson et al. constructed a plasmid shuttle vector that
allows insertion of foreign DNA and stable integration in the
mycobacterial genome by homologous recombination. This
shuttlevectorwasdevelopedtoexpressforeignantigensinM.
smegmatis [20]. The structural instability of several recom-
binant plasmids expressing the cirscumsporozoite protein
(CSP aa 18–391) from Plasmodium falciparum was described
by Haeseleer [21]. The analysis in M. smegmatis and BCG
of numerous rearranged plasmids showed that the presence
of a functional speciﬁc expression cassette was responsible
for the plasmid instability and that the observed deletions
seemed to come from recombination between homologous
and nonhomologous sequences [21].
Kumar et al. monitored the role of such genetic rear-
rangement events in the expression of cloned Escherichia
coli lacZ gene in Mycobacterium smegmatis host strain using
integrative (pMV361::lacZ) and episomal (pMV261::lacZ)
vectors. The lacZ gene present in both vectors was the
mutable target within the vector and simple color detection
assay in mycobacteria was used to screen the genetic rear-
rangements during replication in Mycobacterium smegmatis.
They reported that a loss of lacZ phenotype was due to the
insertion of an IS element in the lacZ gene of the integrative
vector (frequency 1.7 × 10
−5), whereas in the case of the
replicative vector, the loss of lacZ phenotype was due to
deletions of diﬀerent sizes in the lacZ gene and the hsp60
promoter region (frequency 2 ×10
−3)[ 22].
In this study we evaluated the expression of disrupted
heterologous HIV-1gp120 gene, from SHIV-HXBc2P 3.2
clone (GenBank accession number AF041850), by genetic
rearrangements in Mycobacterium bovis BCG host strain
using a replicative vector (pMV261) regulated by BCG
hsp60 promoter (strong promoter). To compare the HIV-
1gp120 gene expression and plasmid DNA stability in vivo,
the replicative (pJH222) and integrative (pJH223) vectors
carryingawild-typelysine-complementinggeneinthelysine
auxotrophof BCGhoststrain wereused. In thesevectors,the
HIV-1gp120 gene expression was regulated by Mycobacteria
spp. α-antigen promoter (weak promoter). We have demon-
strated that the use of weak promoters (Mycobacteria spp. α-
antigen promoter) to regulate HIV-1gp120 gene expression
andBCGlysineauxotrophscomplementedwithalysinegene
do, in fact, prevent the disruption of gene expression caused
by genetic rearrangements.
2.MaterialsandMethods
2.1. Bacterial Strains and Culture Methods. The bacterial
strains used in this study are listed in Table 1. Escherichia
coli cultures were grown in Luria-Bertani (LB) broth (Sigma-
Aldrich, USA) or on LB agar plates (Sigma-Aldrich, USA)
at 37
◦C. LB was supplemented with kanamycin (40μg/mL)
(Sigma-Aldrich, USA). Mycobacterial cultures were grown
in Middlebrook 7H9 broth (Becton-Dickinson, USA) or on
Middlebrook 7H10 agar medium (Becton-Dickinson, USA)
supplemented with 10% albumin-dextrose-catalase (ADC)
(Becton-Dickinson, USA) and containing 0.05% Tween
80 (Sigma-Aldrich, USA) and kanamycin (25μg/mL). The
L-lysine monohydrochloride was purchased from Sigma-
Aldrich (USA), dissolved in distilled water and used at a
concentration of 40μg/mL.
2.2. Construction of Expression Vectors. Tables 2 and 3
listed the parental E. coli/mycobacterial shuttle vectors used
for cloning the HIV-1gp120 gene from SHIV-HXBc2P
3.2 clone (GenBank accession number AF041850) and
the constructs. Plasmid DNA vectors pMV261 (4,480bp),
pJH222 (6,423bp), and pJH223 (6,313bp) were used as
parental plasmids for all plasmid DNA constructs obtained
as described below. The entire DNA coding sequence of
HIV1gp120 (1,578bp) antigen was synthesized by poly-
merase chain reaction (PCR), using oligonucleotide primers
speciﬁc for HIV-1 gp120 gene and cloned into the diﬀerent
E.coli/mycobacterial shuttle vectors.Journal of Biomedicine and Biotechnology 3
Table 1: List of bacterial strains used in this study.
Bacterial strains Relevant characteristics Reference or source
Mycobacterium bovis BCG 1173 P2 Pasteur strain [23]
Mycobacterium bovis BCG mc2 1604 Pasteur ΔlysA5::res [24]
Escherichia coli JM109 recA1 endA1 gyrA96 thi-1 hsdR17 (rK
−mk
+) supE44
relA1 Δ(lac-proAB)/F
 [traD36proAB+ lac I q lacZΔM15] GIBCO BRL
Table 2 :L i s to fp a r e n t a lE. coli/mycobacterial shuttle vectors used in this study.
Plasmid DNAs Relevant characteristics Reference or source
pMV261
E. coli/mycobacterial shuttle vector
[25] Multicopy extrachromosomal vector
Kanamycin resistant
pJH222
pMV261 derivative
Kindly provided by Bloom and Jacobs laboratory Multicopy extrachromosomal vector
Kanamycin resistant
Lysine A complementing gene
PJH223
pMV361 derivative
Kindly provided by Bloom and Jacobs laboratory Monocopy integrative vector
Kanamycin resistant
Lysine A complementing gene
Plasmid DNA pMV261 is a replicative vector (multicopy,
extrachromosomal) that contains a DNA cassette encoding
kanamycin resistance (Tn903-derived aph gene), an E.
coli origin of replication (oriE), a mycobacterial plasmid
DNA origin of replication (oriM), an expression cassette
containing a mycobacterial promoter, a multiple cloning site,
and a transcriptional terminator. For pMV261::HIVgp120,
the HIVgp120 gene was fused to the ﬁrst six codons of the
cytoplasmically expressed BCG hsp60 protein. For immun-
odetection purposes, we fused downstream of the HIV-1
gp120 gene with the inﬂuenza virus hemagglutinin epitope
(HA) coding sequence and six residues of histidine. The
HIV-1 gp120 gene expression was regulated by BCG hsp60
promoter. The primers were designed to incorporate BamHI
(forward 5 -CAAGGATCCGAAATTGTGGGTCACAGTC-
3 ) and HindIII (reverse 5 -CAGAAGCTTCTAGTGGTG-
GTGGTGGT-3 ) sites at the 5  and 3  termini of the
ampliﬁed DNA fragment to be cloned into the pMV261
plasmid DNA at 4,326bp-BamHI/4,346bp-HindIII.
Plasmid DNA pJH222, a derivative of pMV261, contains
also the lysA complementing gene, under the regulatory
control of BCG hsp60 promoter. For the pJH222::HIV-1
gp120 construct, the HIV-1 gp120 gene was fused to the
5  region encoding the 19kDa lipoprotein signal sequence
from Mycobacterium tuberculosis, and the HA epitope and
six residues of histidine were fused downstream. The HIV-
1gp120 gene expression was under the control of Mycobacte-
ria spp. α-antigen promoter. The primers were designed to
incorporate HindIII (forward 5 -CAGAAGCTTGGGCCC-
GAAAAA-3 ) and PstI (reverse 5 -CAACTGCAGCTAGTG-
GTGGT-3 ) sites at the 5  and 3  termini of the ampliﬁed
DNA fragment to be cloned into the pJH222 plasmid DNA
(335bp-HindIII/341bp PstI).
Plasmid DNA pJH223 is an integrative vector (single-
copy, integrated). It contains a DNA cassette encoding
kanamycin resistance (Tn903-derived aph gene), an E. coli
origin of replication (oriE), a DNA segment carrying the
attachment site (attP) and the integrase (int) gene from the
mycobacteriophage L5 [26], the lysA complementing gene
under the regulatory control of BCG hsp60 promoter, and
an expression cassette containing a mycobacterial promoter,
a multiple cloning site and a transcriptional terminator. The
pJH223::HIV-1 gp120 plasmid DNA was constructed using
the same method as for pJH222::HIV-1 gp120. The primers
were designed to incorporate HindIII sites (forward 5 -
CAGAAGCTTGGGCCCGAAAAA-3  and reverse 5 -CAA-
AAGCTTCTGCAGCTAGTGGTGG-3 ) at the 5  and 3 
termini of the ampliﬁed DNA fragment to be cloned into the
pJH223 plasmid DNA (2,134bp-HindIII).
The correct cloning of the HIV-1gp120 gene into the
plasmid DNA and the deletion of the ∼900bp fragment were
conﬁrmed by DNA sequencing, PCR and enzyme restriction
analysis performed following standard protocols [27].
2.3. Electroporation of Mycobacteria. The BCG wild type
host strain was transformed with pMV261::HIV-1 gp120
plasmid DNA and lysine auxotroph of BCG was transformed
with pJH222::HIV-1gp120 and pJH223::HIV1gp120 plasmid
DNA by electroporation. BCG cultureswere grown to an OD
of0.9(600nm),pelletedat3,000rpm,washedtwicebyresus-
pension and centrifugation (3,000rpm) in 10% glycerol at
4◦C and ﬁnally resuspended in 1/20th of the original culture
volume with cold 10% glycerol. Then 100μL of the cold BCG
suspension was mixed with plasmid DNA (50–500ng) in a4 Journal of Biomedicine and Biotechnology
Table 3: Constructs obtained using E. coli/mycobacterial shuttle expression vectors to express HIV-1gp120 antigen (HXBc2).
Constructs Promoter Secretion signal Resistance
Gene
Complementing
gene Tag
pMV261:HIV-1 gp120 BCG hsp60 None Kanamycin None HA
His
pJH222:HIV-1 gp120 α-antigen of
Mycobacterium spp
19 kDa lipoprotein (M.
tuberculosis) Kanamycin Lysine HA
His
pJH223:HIV-1 gp120 α-antigen of
Mycobacterium spp
19 kDa lipoprotein (M.
tuberculosis) Kanamycin Lysine HA
His
HA: hemagglutinin epitope tag from inﬂuenza virus; His: Histidine residues.
prechilled 0.2cm electroporation cuvette and transformed
using the Biorad Gene Pulser electroporator at 2.5kV, 25mF,
and 1,000Ω. After electroporation 1ml of 7H9 medium,
supplemented with ADC and containing 0.05% Tween 80,
was added and incubated at 37
◦C for 12 hours before plating
on Middlebrook agar 7H10 medium supplemented with
10% ADC and containing 0.05% Tween 80 and kanamycin
(25μg/mL).
2.4. Detection of the Fragment DNA Deletion. After trans-
formation by electroporation, the rBCG colonies were used
as templates for the PCR analysis. Diﬀerent rBCG colonies
were inoculated into 50μL of distilled water, vortexed and
1μL was used for the PCR analysis. Speciﬁc primers for
cloning the HIV-1 gp120 gene into pMV261, pJH222 and
pJH223 vectors were used. The plasmid DNA before BCG
transformation (pre-BCG) was used as positive control for
the PCR analysis.
2.5. Mycobacterial Plasmid DNA Isolation for DNA Sequenc-
ing and Enzyme Restriction Mapping. The QIAprep Spin
Miniprep Kit (Qiagen, Hilden, Germany) was used for E.
coli and mycobacteria plasmid DNA puriﬁcation. Diﬀerent
rBCG colonies that showed the DNA fragment deletion by
PCR analysis were inoculated in mycobacterial broth culture
up to an OD of 0.9 (600nm). This BCG culture was used
for mycobacterial plasmid DNA isolation. For mycobacteria,
the standard QIAprep Spin Miniprep protocol was used
with a slight modiﬁcation: after resuspension in buﬀer P1,
lysozyme was added at a concentration of 10mg/mL and
samples were incubated at 37
◦C overnight. For improving
the puriﬁed plasmid yield, the mycobacterial plasmid DNAs
from selected rBCG colonies were transformed in E. coli
JM109 using 5μL of the isolated plasmid DNAs, and
puriﬁed according to the manufacturer’s instructions for
DNA sequencing and enzyme restriction mapping. The
plasmid DNA before BCG transformation (pre-BCG) was
used as positive control for the enzyme restriction analysis.
The nucleotide sequences were obtained using the BigDye
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems,
USA) and ABI PRISM 3100 Genetic Analyzer. Multiple
DNA sequence alignments were performed using the Clustal
software.
2.6.WesternBlotAnalysis. BCGtransformantsweregrownto
mid-logarithmic phase in liquid 7H9 medium supplemented
with 10% ADC and containing 0.05% Tween 80 and
kanamycin (25μg/ml). rBCG cultures were centrifuged at
3,000rpm for 10minutes at 4◦C. Pellets were washed twice
in Phosphate Buﬀered Saline (PBS) plus 0.02% Tween 80
and resuspended in 1ml of extraction buﬀer (50mM Tris-
HCl pH 7.5, 5mM EDTA, 0.6% sodium dodecyl sulfate),
and added with 5μl of 100x protease inhibitor cock-
tail (1mg/ml aprotinin, 1mg/ml E-64, 1mg/ml leupeptin,
1mg/ml pepstatin A, 50mg/ml pefabloc SC, and 10ml
dimethylsulfoxide).Cellsweresonicatedfor4minutesonice
with a Branson sonicator at output control seven and duty
cycle of 50%. Extracts were centrifuged at 13,000rpm for
10minutes at 4◦C and supernatants were collected. Proteins
were separated on 15% SDS-polyacrylamide gel. After elec-
troblotting, nitrocellulose membranes were ﬁrst probed with
a 1:1000 dilution of mouse monoclonal antibody HA.11
(Covance, USA) directed to inﬂuenza virus hemagglutinin
epitope (YPYDVPDYA) followed by a 1:2000 dilution of
horseradish peroxidase (HRP)-conjugated antibodies. The
membranes were developed using chemoluminiscent ECL
(GE Healthcare, USA) as HRP substrate.
3. Results
3.1. PCR Detected a ∼900bp-DNA Fragment Deletion in
the HIV-1gp120 Gene. As shown in Figure 1, PCR analysis
of rBCG:HIV-1gp120(pMV261) colonies detected a partial
deletion of the HIV-1gp120 DNA coding sequence using the
speciﬁcprimersthatwereusedforcloningtheDNAsequence
into the pMV261 vector. This deletion was reproduced in 12
out of 14 rBCG:HIV-1 gp120 (pMV261) colonies analyzed
(data not shown). In addition, this partial deletion was
observedonlybyPCRofplasmidDNAfromBCGcoloniesin
which the HIV-1gp120 DNA fragment was inserted into the
pMV261 vector and the gene expression was regulated by the
hsp60 promoter from BCG (Figure 1, lane 2). The deletion
wasnotdetectedwhentheDNAfragmentencodingtheHIV-
1gp120 antigen was cloned into pJH222 and pJH223 vectors
under Mycobacteria spp. α-antigen promoter regulation
(Figure 1, lanes 4 and 6). The deletion was not detected in
all10rBCG:HIV-1gp120(pJH222)coloniesscreenedbyPCR
(data not shown).Journal of Biomedicine and Biotechnology 5
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Figure 1: PCR analysis of the HIV-1gp120 gene cloned into
pMV261, pJH222 and pJH223 vectors. Lane 1, 3 and 5 are PCR
products of the HIV-1gp120 gene (1578bp) cloned into pMV261
(lane 1), pJH222 (lane 3) and pJH223 (lane 5) vectors, respectively.
Plasmid DNA before BCG transformation (pre-BCG) were used
as positive controls (lane 1, 3 and 5). Lane 2, 4 and 6 are
PCR products from the rBCG:HIV-1gp120 (pMV261), rBCG:HIV-
1gp120 (pJH222) and rBCG:HIV-1gp120 (pJH223) colonies.
3.2. Enzymatic Restriction Analysis Revealed a ∼900bp-
DNA Fragment Deletion. We also compared the restriction
enzyme digestion proﬁle of the pMV261 and pJH222
plasmid DNA vectors with and without heterologous HIV-
1gp120 DNA insert, pre- and post-BCG transformation
(Figure 2). The pMV261 plasmid DNA vector without the
DNAinsertcorrespondingtoHIV-1gp120genedidnotshow
any diﬀerence in the enzymatic restriction proﬁles from pre-
and post-BCG transformations (Figure 2, lanes 1 and 2).
The same result was obtained for the pJH222 plasmid DNA
vector containing the DNA insert (Figure 2,l a n e s5a n d6 ) .
In contrast, the pMV261 containing the HIV-1gp120 insert
showeddiﬀerentenzymaticrestrictionproﬁlesfrompre-and
post-BCG transformations (Figure 2,l a n e s3a n d4 ) .
3.3.The ∼900bp-PartialDNAFragmentDeletionCorresponds
to the HIV-1gp120 Core. Following sequence analysis and
molecular characterization of the deleted DNA fragment
in the 10 rBCG:HIV-1gp120 (pMV261) mutant colonies,
we demonstrated that the partial deletion (∼900bp) corre-
sponds to gp120 core rich in potential glycosylation sites and
thevariableregionsV3,V4,andV5ofHIV-1env,ak eystruc-
ture involved in the HIV union to its receptor (CD4) and co-
receptor on the host cell surface. Strikingly, the deleted DNA
fragment in the rBCG mutants contained the DNA sequence
coding for HIV-1 envelope immunodominant CTL, murine
H-2Dd-restricted epitope P18-I10 (Figure 3). Deletion in
HIV-1gp120 gene was not observed in any rBCG:HIV-
1gp120 (pJH222) and rBCG:HIV1gp120 (pJH223) colonies
that carry the pJH222:HIV-1gp120 and pJH223:HIV1gp120
vectors containing the Mycobacteria spp. α-antigen promoter
to regulate the HIV1gp120 gene expression, indicating that
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Figure 2: Enzymatic restriction analysis of pMV261::HIV-1gp120
and pJH222::HIV-1gp120 plasmid DNA after BCG transformation.
Lane 1, pMV261 plasmid DNA without HIV-1 gp120 DNA insert
digested with BglII; Lane 2 pMV261 plasmid DNA without HIV-
1 gp120 DNA insert from BCG colonies, digested with BglII, Lane
3, pMV261-HIV-1gp120 plasmid DNA digested with SacII; lane
4, pMV261-HIV-1gp120 plasmid DNA from rBCG:HIV-1gp120
colonies, digested with SacII; lane 5, pJH222-HIV-1gp120 plasmid
DNA digested with HpaI and lane 6, pJH222-HIV-1gp120 plasmid
DNA from rBCG:HIV-1 gp120 colonies, digested with HpaI.
Plasmid DNAs before BCG transformation (pre-BCG) were used
as positive controls (lane 1, 3 and 5).
the deletions were not due solely to the toxic eﬀects of HIV-
1gp120 expression during growth of the recombinant BCG
strains.
3.4. A Truncated Protein Was Expressed in rBCG Mutants
That Show the ∼900bp-DNA Fragment Deletion. Expression
of HIV-1gp120 protein by rBCG:HIV-1gp120 (pMV261 and
pJH222) strains was conﬁrmed by SDS-PAGE and western
blot analysis of whole-cell BCG lysates. The chimeric 19kDa
lipoprotein signal sequence-HIV-1gp120-Flu-His recombi-
nant protein, with a relative molecular mass (Mr) of
67kiloDalton (kDa) was present in lysates of rBCG:HIV-
1gp120 (pJH222) bacterial cells containing the 1.82kilobase-
pair (kbp) HIV-1gp120 DNA coding sequence in pJH222
vector. The apparent Mr of HIV-1gp120 protein was consis-
tent with that predicted by the gene sequence without post-
translation modiﬁcation. By contrast, when all rBCG:HIV-
1gp120(pMV261)mutantcolonieswereanalyzedbywestern
blot, we detected a band of 28kDa (truncated protein)
instead of the expected 67kDa protein (Figure 4).
4. Discussion
Mycobacterium tuberculosis infection is a major cause of
human morbidity and mortality, and vaccine is the most
cost-eﬀectiveintervention to prevent disease. Mycobacterium
bovis BCG is a widely used vaccine against tuberculosis, and
a single dose given at birth confers long-lasting immunity.
Mycobacterium bovis BCG has been suggested as an ideal
delivery system for expression of foreign antigens due to
the long persistence of BCG in the immunized host. Thus,
Mycobacterium bovis BCG not only is used as vaccine against6 Journal of Biomedicine and Biotechnology
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Figure 3: Multiple HIV-1gp120 DNA sequence alignment carrying the ∼900-bp deletion from the mutant rBCG:HIV-1gp120 (pMV261)
colonies. HIV-1gp120 DNA sequences of 10 mutant rBCG:HIV-1gp120 (pMV261) colonies were aligned and compared with the parental
nucleotide sequence of the HIV-1gp120 gene. The ∼900bp deleted fragment (sequence and position shown in the scheme) structurally
corresponds to the gp120 core (see protein translation).
tuberculosis, but also oﬀers great potential for innovative
approaches for development of polyvalent vaccines [25, 28–
30]. In vivo genetic stability and persistence are of special
importance for the use of live bacterial vaccines. A mutant
BCG which is rapidly eliminated by the host immune
system is unlikely to be an eﬀective vaccine [31]. The
rearrangement of DNA is one of the fundamental properties
oflife,includingbothprokaryotesandeukaryotes,withgreat
biological signiﬁcance. Some of these DNA rearrangements
are important in controlling gene expression in speciﬁc cell
types; others may play an evolutionary role by contributing
to genetic diversity.
Some studies using episomal vectors in rBCG reported
high levels of stability in vitro. For example, plasmids
responsible for expressing M. Tuberculosis α-antigen in BCG
were stable over six consecutive 4-week cultures without
selection and changes in the level of expression [32]. An
α-antigen-HIV-1 V3J1 chimeric protein was secreted by
rBCG for at least 450 passages in vitro [33]. However, in
vitro instability of episomal vectors has also been reported
regularly. Lim et al. [34] described that expression of
SIV mac 251 env (aminoacids, aa, 1-245) by rBCG was
stable in culture (pBlaF promoter), but rBCG harboring
the same vector containing aa 1-521 or aa 215-521 were
unstable. Chawla and Das Gupta [35] reported that the
disruption of pAL5000-derived vectors in M.smegmatis
through transposition of an insertion sequence upstream of
the kanamycin resistance gene led to structural instability
and large deletions. Kumar et al. studied the stability of
the expression of Escherichia coli β-galactosidase under theJournal of Biomedicine and Biotechnology 7
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Figure 4: Expression of HIV-1gp120 protein in rBCG:HIV-1gp120 (pMV261) and rBCG:HIV-1gp120 (pJH222) strains by Western blot
analysis of whole-cell BCG lysates. (a) A band of ∼28kDa was detected when analizing the rBCG:HIV-1gp120 (pMV261) colonies. (b) A
67kDa protein was detected in lysates of rBCG:HIV-1gp120 (pJH222) bacterial cells containing the 1.82 kilobase (kb) HIV-1gp120 DNA
coding sequence into pJH222 vector. The gp120 expression was determined using anti-HA MAb. Not transformed BCG (BCG wild type)
were utilized as negative controls. (c) The HIV-1gp120 (HXBc2) gene was cloned into the E.coli/mycobacteria shuttle plasmids pMV261
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M.Tuberculosis α-antigen promoter (P α-Ag). Both plasmids contained kanamycin resistance gene (aph) and an E.coli origin of replication
(ori E) and a mycobacterial origin of replication (oriM). In addition, pJH222 contained the complementing lysA gene. The HIV-1gp120
gene was fused to the ﬁrst six codons of BCG hsp60 (pMV261) or fused to M. tuberculosis 19-kDa lipoprotein signal sequence (pJH222).
MWM, molecular weight markers.
control of hsp60 promoter in Mycobacterium smegmatis
using integrative and replicative vectors. In the case of
replicative vectors, they detected higher frequencies of
lacZ expression inactivation as compared with the same
lacZ cassette, when present in integrated state [22]. How-
ever, Springer et al. [36] reported a high-frequency loss
of pMV361-based integrating vectors from M. smegmatis
and BCG. Al-Zarouni and Dale investigated the eﬀects
of various combinations of posttranslational signals and
promoters on heterologous gene expression and stability
in diﬀerent BCG strains. Plasmid DNAs were constructed
using mycobacterial promoters (hsp60, 19-kDa antigen,
85A antigen, from Mycobacterium tuberculosis complex,
and the 18-kDa antigen from Mycobacterium leprae)a n d
post-translation signals (85A antigen secretion and 19-kDa
antigen acylation signals), coupled with reporter genes. They
provided evidence that the 85A secretion signal markedly
enhanced the levels of cell-associated product, while the 19-
kDa acylation signal had little eﬀect on gene expression.
This group also demonstrated that the hsp60 promoter
caused plasmid DNA instability and showed that various
deletions in the promoter region occurred during or soon
after transformation, but not during subsequent growth of
the transformants, nor with other promoters [37]. Gross8 Journal of Biomedicine and Biotechnology
instability was also observed when the episomal vectors were
used to express rotavirus VP6 protein under the control of
hsp60 promoter [38]. The possibility of inserting foreign
genes into the chromosome at precise positions to ensure
the persistence of the heterologous genetic information in
the recombinant vaccine strains would represent a crucial
step in the development of Mycobacterium bovis BCG as a
live vaccine vector for expression of heterologous antigens
[28, 39]. Even though integrative plasmid DNAs have been
shown to be more stable as they are incorporated into
the chromosome via homologous recombination, Baulard
and colleagues demonstrated that with replicating plasmid
DNAs, relatively high levels of homologous recombination
were obtained in fast- and slow-growing mycobacteria,
and 100% of the selected clones underwent homologous
recombination [40].
Thus, if BCG is to be used as a live bacterial carrier for
generating novel vaccine candidates and as an immunother-
apeutic agent, it is essential that a more genetically stable
strain be developed. Sander and collaborators demonstrated
that Mycobacterium bovis BCG recA mutants are a valuable
tool for the further development of BCG as an antigen
delivery system to express foreign antigens and as a source
of a genetically stable vaccine against tuberculosis [41]. This
was conﬁrmed in a study performed by Keller and coworkers
where it was observed that recA inactivation in BCG Russia
strain was in part responsible for its high degree of genomic
stability, resulting in a substrain that has fewer genetic
alterations than other vaccine substrains with respect to M.
bovis AF2122/07 wild-type [42].
Expression of HIV genes in BCG is not always possible.
Lack of success in this respect may be due to overexpression
of lethality or other forms of protein toxicity. Stover et al.
were unable to express HIV-1 gp120 (hsp60 promoter) from
an episomal vector, but could express it from an integrative
vector [19, 25].
In our study, we have observed that, in the case of the
replicative pMV261 vector, disruption of HIV-1gp120 gene
expression was due to a consensus DNA fragment deletion
in the HIV1gp120 gene detected in all ten diﬀerent BCG
clones. By contrast, we did not detect any HIV-1gp120
gene expression disruption in the replicative (pJH222) and
integrative (pJH223) vectors. Sequence analysis indicated
that the DNA fragment deletion contained several potential
glycosylation sites, the variable regions V3, V4 and V5 and a
CTL immunodominant epitope (P18-I10 peptide). Based on
this observation, we hypothesized that the loss of expression
of this immunodominant epitope could help mycobacteria
to escape the host’s immunological response and may
represent part of an ongoing adaptation to survival in host
environments that are screened by immunological defense
mechanisms. Huber and collaborators have described a
natural loss of expression of highly immunogenic proteins
caused by a variety of genomic changes in Mycobacterium
ulcerans that may confer a selective advantage to this
emerging pathogen [43]. On the other hand, the deleted
DNA sequence in the rBCG:HIV-1gp120(pMV261) mutant
colonies analyzed in our study (n = 10) was highly
conserved, which is in disagreement with Dennehy et al. that
deletions in the VP6 heterologous gene (hsp60 promoter) in
rBCG were random and diﬀerent among clones examined
[38].
We have demonstrated that the use of weak promoters
(Mycobacteria spp. α-antigen promoter) to regulate HIV-
1gp120 gene expression and BCG lysine auxotrophs comple-
mented with a lysine gene do, in fact, prevent the disruption
of gene expression caused by genetic rearrangements. The
results showed that such genetic rearrangements can signiﬁ-
cantly aﬀect the expression of foreign genes in mycobacteria.
Thus,itcouldresultinanrBCGthatdoesnotinduceoptimal
immune responses to the HIV antigen.
Mycobacterium bovis Bacillus Calmette-Gu´ erin (BCG) as
a live vector of recombinant bacterial vaccine is a promising
system to be used. However, few promising approaches
have emerged in the last ﬁve years to overcome the genetic
instability in rBCG-based vaccines. To prevent the plasmid
instability in vivo and in vitro and the genetic rearrangement
by mycobacteria, diﬀerent approaches should be considered:
(i) the use of expression vectors containing small HIV DNA
coding sequences, (ii) DNA fragments lacking glycosilation
sites, (iii) the use of weak promoters, (iv) the use of
BCG auxotrophic strains (containing the complementing
gene in the expression vectors), (v) the use of inducible
promoters, (vi) codon optimization of the recombinant
gene, (vii) the choice of expression vector backbone and
(viii) antigen secretion to enhance the immunogenicity
and to prevent foreign proteins from becoming toxic to
BCG.
In ﬁve years’ time we will have a better picture of how the
immuneresponsesinducedbyrBCGcouldbeenhanced,and
what sort of route, doses, immunization schedule, timing for
immunological assays are likely to induce optimal responses
in mice and monkeys. Heterologous prime-boost regimen,
diﬀerent immunization schedule, routes and doses, should
be performed to evaluate the potential for enhancing speciﬁc
immune responses.
Mycobacterium Bovis BCG is a promising approach as a
bacterial live recombinant vaccine vehicle. BCG has a long
record of safe use in humans and is able to induce long-
lasting immunity. In addition, it could be the best hope
for protecting newborn infants, reducing the adult burden
of HIV infection and protecting neonates against vertical
transmission.
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